Should polymyxin be used empirically to treat infections in patients under high risk for carbapenem-resistant Acinetobacter ?

Saved in:
Bibliographic Details
Published in:The Journal of infection 2011-03, Vol.62 (3), p.246-249
Main Authors: Tuon, Felipe F, Rymsza, Andrea M, Penteado-Filho, Sergio R, Pilonetto, Marcelo, Arend, Lavinia N, Levin, Anna S
Format: Article
Language:English
Subjects:
Acinetobacter - drug effects
Acinetobacter - isolation & purification
Acinetobacter Infections - drug therapy
Acinetobacter Infections - microbiology
Acinetobacter Infections - mortality
Adolescent
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents - therapeutic use
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacteremia - drug therapy
Bacteremia - microbiology
Bacteremia - mortality
beta-Lactam Resistance
Biological and medical sciences
Brazil
Carbapenems - therapeutic use
Child
Cross Infection - drug therapy
Cross Infection - microbiology
Cross Infection - mortality
Female
General aspects
Humans
Infectious Disease
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Polymyxins - therapeutic use
Survival Analysis
Young Adult
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2011.01.005